Anti-CD38 IgG1 monoclonal antibody that depletes CD38-positive cells via ADCC/CDC/ADCP and may reduce adenosine-mediated immunosuppression.
Human IgG1κ anti-CD38 monoclonal antibody that binds CD38 on tumor and immunosuppressive cells, inducing Fc-mediated cytotoxicity and phagocytosis (ADCC, CDC, ADCP) to deplete CD38+ cells and reduce adenosine-mediated immunosuppression.
Daratumumab binds CD38 on target cells and via its Fc engages effector mechanisms—ADCC (NK cells), CDC (complement), and ADCP (macrophages)—resulting in lysis and phagocytosis of CD38+ cells.
Humanized IgG1 monoclonal antibody against EGFR/HER1 (ErbB1) that blocks ligand binding and receptor activation, inhibits downstream EGFR signaling, and may induce antibody-dependent cellular cytotoxicity (ADCC).
Humanized IgG1 monoclonal antibody targeting EGFR (HER1) that binds the extracellular domain to block ligand binding and receptor activation/dimerization, suppressing downstream EGFR signaling (RAS/RAF/MEK/ERK and PI3K/AKT) to inhibit tumor-cell proliferation and survival; may also mediate ADCC.
IgG1 anti‑EGFR antibody binds EGFR on target cells and its Fc engages FcγR on immune effectors (e.g., NK cells) to trigger ADCC, killing EGFR+ cells; signaling blockade is mainly cytostatic.
An off-the-shelf, allogeneic NK-92–derived CAR-NK cell therapy engineered to express an anti-CD19 CAR for direct killing of CD19+ B cells, secrete ER-retained IL-2 to support NK activation/persistence, and express high-affinity CD16a (FcγRIIIa V158) to enhance ADCC.
Allogeneic NK-92–derived CAR-NK cells engineered with an anti-CD19 chimeric antigen receptor to recognize and kill CD19+ B cells via NK cytotoxic mechanisms (perforin/granzyme). The cells secrete ER-retained IL-2 to support NK activation and persistence and express high-affinity CD16a (Fc-gamma RIIIa V158) to enhance antibody-dependent cellular cytotoxicity, enabling synergy with therapeutic antibodies.
Anti-CD19 CAR on NK-92–derived cells binds CD19 and triggers NK degranulation (perforin/granzyme) to kill CD19+ cells; high-affinity CD16a can add ADCC when antibodies are present.
A chimeric IgG1 monoclonal antibody against CD20 that depletes B cells via antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, and apoptosis.
Chimeric IgG1 monoclonal antibody targeting CD20 on B cells; depletes CD20-positive cells primarily via Fc-mediated antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, and induction of apoptosis.
Anti-CD20 antibody opsonizes B cells and triggers Fc-mediated ADCC by NK cells/macrophages, activates complement-dependent cytotoxicity, and can induce apoptosis of CD20+ cells.
Rabbit-derived polyclonal IgG targeting human T-cell antigens; depletes T cells (and some B/NK cells) via complement-dependent cytotoxicity, ADCC, and apoptosis.
Rabbit-derived polyclonal IgG that binds multiple human T‑cell antigens and depletes T cells (with some B/NK cell effects) via complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, and induction of apoptosis, producing profound lymphodepletion.
rATG contains antibodies to CD2 that bind CD2+ cells and induce complement-dependent cytotoxicity and Fc-mediated ADCC, with additional apoptosis, depleting CD2-expressing cells.